APO-TAMOX TAB 10MG 10 MG — DIN 00812404
TAMOXIFEN (TAMOXIFEN CITRATE) : 10 MG · APOTEX INC · TABLET · wholesale supply in Canada
Health Canada status: MARKETED
What is APO-TAMOX TAB 10MG?
APO-TAMOX TAB 10MG 10 MG contains TAMOXIFEN (TAMOXIFEN CITRATE) : 10 MG. It is listed in the Health Canada Drug Product Database under DIN 00812404, held by APOTEX INC, supplied as TABLET for ORAL administration. Health Canada currently lists it as marketed, status dated 31-Dec-1989. Nexara Health is a licensed Canadian wholesale distributor (DEL 3-002896-A) and can source this product for hospitals, pharmacies and clinics. Availability and lead time are confirmed per order.
What is APO-TAMOX TAB 10MG used for?
Adjuvant treatment of early breast cancer (ER+); treatment of hormone responsive locally advanced or metastatic breast cancer.
Authorized indication as written in the Health Canada product monograph. For healthcare professionals and licensed purchasers; this is not medical advice.
How much does Tamoxifen cost around the world?
Tamoxifen is listed on 9 of the national price registers Nexara ingests. Each country publishes on a different basis, so those figures are not comparable with one another — or with a Canadian wholesale price.
What a market publishes matters more than the number it publishes. Australia publishes a ex-manufacturer; Greece publishes a producer price (ex-factory); Hungary publishes a producer price (ex-factory). Comparing an ex-factory ceiling against a pharmacy public price tells you nothing about either, and comparing either against a Canadian landed cost tells you less.
| Market | Price basis published there | Brands | Packs listed | Range |
|---|---|---|---|---|
| Australia | ex-manufacturer | 5 | 14 | AUD███.██ |
| United States | acquisition | 2 | 13 | USD███.██ |
| Saudi Arabia | public | 8 | 11 | SAR███.██ |
| South Africa | single exit price | 7 | 9 | ZAR███.██ |
| Sweden | AIP (pharmacy purchase price) | 4 | 6 | SEK███.██ |
| Greece | producer price (ex-factory) | 3 | 3 | EUR███.██ |
| United Kingdom | hospital | 2 | 2 | GBP███.██ |
| Hungary | producer price (ex-factory) | 1 | 1 | HUF███.██ |
| Romania | max producer price | 1 | 1 | RON███.██ |
60 pack listings across 33 brand entries and 8 price bases, refreshed 08 Sep 2026. Ranges span every Tamoxifen pack in that market, so a high figure is usually a larger pack rather than the same product.
Canada publishes no comparable public list price. For a delivered Canadian price on a licensed account, verify your licence — it takes about a minute.
Is there a generic Tamoxifen in Canada, and who makes it?
Every market authorization holder with a Canadian DIN for this molecule, and how many of their listings Health Canada currently shows as marketed.
12 holders have a Canadian DIN containing Tamoxifen, across 24 DINs, of which 4 are currently marketed. Marketed count is the number that matters: an approval that is not marketed cannot be bought.
| Market authorization holder | DINs | Marketed | Brand names | Position |
|---|---|---|---|---|
| APOTEX INC | 2 | 2 | APO-TAMOX TAB 10MG, APO-TAMOX TAB 20MG | Sourceable in Canada |
| TEVA CANADA LIMITED | 2 | 2 | TEVA-TAMOXIFEN | Sourceable in Canada |
| ADRIA LABORATORIES OF CANADA LTD. | 2 | 0 | TAMONE TAB 10MG, TAMONE TAB 20MG | No marketed DIN |
| ASTRAZENECA CANADA INC | 2 | 0 | NOLVADEX TAB 10MG, NOLVADEX-D TAB 20MG | No marketed DIN |
| DOMINION PHARMACAL | 2 | 0 | DOM-TAMOXIFEN | No marketed DIN |
| DUPONT MERCK PHARMA INC. | 2 | 0 | TAMOPLEX TAB 10MG, TAMOPLEX TAB 20MG | No marketed DIN |
| MYLAN PHARMACEUTICALS ULC | 2 | 0 | MYLAN-TAMOXIFEN | No marketed DIN |
| PFIZER CANADA ULC | 2 | 0 | TAMONE - (10 MG), TAMONE - (20 MG) | No marketed DIN |
| PHARMASCIENCE INC | 2 | 0 | PMS-TAMOXIFEN | No marketed DIN |
| PHARMEL INC | 2 | 0 | TAMOXIFEN | No marketed DIN |
| PRO DOC LIMITEE | 2 | 0 | TAMOXIFENE - 10, TAMOXIFENE - 20 | No marketed DIN |
| SANOFI-AVENTIS CANADA INC | 2 | 0 | TAMOFEN 10, TAMOFEN 20 | No marketed DIN |
Health Canada’s Drug Product Database does not flag which listing is the originator and which are subsequent-entry products, so Nexara does not label them here. Interchangeability is determined provincially, not federally — confirm for your province before a formulary switch. Nexara can confirm which of these is actually obtainable, and on what lead time, per order.
How is it supplied and stored?
Pack configuration, storage class and the handling constraints that drive cold-chain planning. One DIN can cover more than one pack size, and the pack — not the DIN — is what gets priced, shipped and invoiced.
| Strength on the label | 10 MG |
|---|---|
| Dosage form | TABLET |
| Route | ORAL |
| Pack configuration (monograph) | 10 mg: Bottles of 100 and 500. 20 mg: Bottles of 100 and 250. |
| Storage | Not explicitly detailed in provided text (Section 11 header present but content truncated), though general stability is implied. |
Before an order line is unambiguous Nexara needs the strength, the pack size and the presentation.
Substance and classification
| Active substance | Tamoxifen |
|---|---|
| ATC code | L02BA01 |
| AHFS class | 10:00.00 |
| Biosimilar biologic | No |
Health Canada record and identifiers
The regulatory facts straight from the Drug Product Database, plus every identifier form Nexara accepts on a purchase order. A DIN written without its leading zeros is the commonest reason an order line fails to match.
| DIN (8-digit, as used in ordering) | 00812404 |
|---|---|
| DIN (unpadded, as printed on some documents) | 812404 |
| Brand name | APO-TAMOX TAB 10MG |
| Generic / active ingredient | TAMOXIFEN (TAMOXIFEN CITRATE) : 10 MG |
| Market authorization holder | APOTEX INC |
| Health Canada schedule | Prescription |
| ATC code | L02BA01 |
| ATC anatomical main group | L — Antineoplastic and immunomodulating agents |
| ATC therapeutic subgroup | L02BA |
| Current status | MARKETED |
| Status date | 31-Dec-1989 |
| Original market date | 1989-12-31 00:00:00 |
| Status source | Live Health Canada DPD sync |
Verify on the primary sources
How is it administered?
20 to 40 mg daily in single or two divided doses. In early disease, recommended duration is 5 years. Splitting 20 mg tablets is not recommended.
Included because it drives pack selection and wastage. Consult the monograph.
Contraindications
Hypersensitivity to drug/ingredients; pregnancy; history of stroke, DVT, or pulmonary embolism (when used in prevention setting); increased risk of endometrial cancer.
Warnings and precautions
Serious risks: uterine malignancies, stroke, pulmonary embolism, and DVT. May prolong QTc interval. Risk of hypercalcemia in patients with bone metastases.
What can be used instead?
Alternatives on every axis a buyer actually considers — the same molecule in another presentation, the same class, an adjacent class, or a fixed-dose combination. Every row is led by the marketed DIN count, because that is what can be bought this week.
1 · Same molecule, other Canadian presentations
4 of 24 Canadian DINs for this molecule are currently marketed. Marketed products are listed first.
| Product | Strength | Form | Holder | Health Canada status | DIN |
|---|---|---|---|---|---|
| APO-TAMOX TAB 20MG | 20 MG | TABLET | APOTEX INC | MARKETED | 00812390 |
| TEVA-TAMOXIFEN | 20 MG | TABLET | TEVA CANADA LIMITED | MARKETED | 00851973 |
| TEVA-TAMOXIFEN | 10 MG | TABLET | TEVA CANADA LIMITED | MARKETED | 00851965 |
| DOM-TAMOXIFEN | 20 MG | TABLET | DOMINION PHARMACAL | CANCELLED PRE MARKET | 02237599 |
| DOM-TAMOXIFEN | 10 MG | TABLET | DOMINION PHARMACAL | CANCELLED POST MARKET | 02237598 |
| MYLAN-TAMOXIFEN | 20 MG | TABLET | MYLAN PHARMACEUTICALS ULC | CANCELLED POST MARKET | 02089858 |
| MYLAN-TAMOXIFEN | 10 MG | TABLET | MYLAN PHARMACEUTICALS ULC | CANCELLED POST MARKET | 02088428 |
| NOLVADEX TAB 10MG | 10 MG | TABLET | ASTRAZENECA CANADA INC | CANCELLED POST MARKET | 02048477 |
| NOLVADEX-D TAB 20MG | 20 MG | TABLET | ASTRAZENECA CANADA INC | CANCELLED POST MARKET | 02048485 |
| PMS-TAMOXIFEN | 10 MG | TABLET | PHARMASCIENCE INC | CANCELLED POST MARKET | 02237459 |
2 · Same class — other molecules in ATC L02BA
| Molecule | Canadian brands | DINs | Marketed | Sourceable |
|---|---|---|---|---|
| Fulvestrant | ACT FULVESTRANT · APO-FULVESTRANT · FASLODEX · FULVESTRANT INJECTABLE · +2 more | 12 | 6 | Yes |
| Tamoxifen | APO-TAMOX TAB 10MG · APO-TAMOX TAB 20MG · DOM-TAMOXIFEN · MYLAN-TAMOXIFEN · +15 more | 24 | 4 | Yes |
A molecule with zero marketed DINs cannot be sourced domestically, however many approvals it holds — if one of these sits on a formulary or in an older protocol, that is the line to check.
3 · Adjacent classes in ATC L02B
| ATC subgroup | Molecules | DINs | Marketed |
|---|---|---|---|
| L02BG | Aminogluthetimide · Anastrozole · Exemestane · Formestane · Letrozole | 79 | 39 |
| L02BX | Abiraterone · Degarelix · Relugolix | 27 | 20 |
| L02BB | Apalutamide · Bicalutamide · Darolutamide · Enzalutamide · Flutamide · +1 more | 46 | 11 |
Not clinical advice. These tables describe what can be supplied in Canada, not what should be prescribed. Substitution within or across classes is a prescriber and pharmacist decision, and interchangeability is determined provincially.
What else is APO-TAMOX TAB 10MG called?
The same molecule, Tamoxifen, is registered under other names elsewhere. Buyers and prescribers searching from outside Canada — or working from a foreign prescription or tender document — often know it by one of these:
| Name | Script | Registered in |
|---|---|---|
| Nolvadex-D | Latin | Australia |
| Tamoxifen Sandoz | Latin | Australia, Sweden |
| GenRx Tamoxifen | Latin | Australia |
| Neophedan | Latin | South Africa |
| Tamosin | Latin | Australia |
| Tamoxifen Ebb | Latin | Sweden |
| Farshias | Latin | Saudi Arabia |
| Nolvadex- D | Latin | South Africa |
| Tamoxifen Orifarm | Latin | Sweden |
| Tamoxifen Viatris | Latin | Sweden |
| Tremofid | Latin | South Africa |
Names are taken from national medicine registers and published price lists. A product registered abroad is not authorized for sale in Canada unless it holds its own DIN; import is possible only through the routes Health Canada permits.
How can I get it?
Nexara Health supplies this product to licensed Canadian buyers — pharmacies, hospitals, clinics, licensed distributors, and clinical trial sponsors or their CROs. We confirm stock, pack size, expiry and pricing at the time of quotation. If the product is on backorder or in shortage, we identify equivalent alternatives and import options where permitted.
Ordering questions
Who can buy this from Nexara?
Licensed entities only. Nexara holds Health Canada establishment licence DEL 3-002896-A and ships only to a licensed address. Patients and unlicensed buyers are routed to a partner pharmacy.
Is there a minimum order?
Yes, set per product line and per pack multiple rather than on the order total, so you are never asked to buy a part-pack. The minimum for this line is confirmed with your quote.
What is the lead time?
Confirmed per order at quotation, and it depends on current stock position and whether the product is in shortage.
Why is there no price on this page?
Nexara quotes a delivered Canadian price per order, against a verified licence. Foreign list prices are published on incompatible bases and are not a guide to what any buyer can obtain here, so this page shows which markets list the molecule and on what basis, and nothing more.
Can Nexara supply this for a clinical trial?
Yes — comparator and background-therapy supply, including sourcing from other markets where a Canadian pack will not satisfy the protocol. Clinical trial supply.